AKT1 and breast carcinoma: Because the doxorubicin-induced activation of Akt is dependent on PI3-K activity, we proposed that the breast cancer cells with compelling molecular components of the PI3-K pathway might show an enhanced cellular response to doxorubicin-induced activation of Akt.